Skip to main content
Fig. 6 | BMC Anesthesiology

Fig. 6

From: Bupivacaine suppresses the progression of gastric cancer through regulating circ_0000376/miR-145-5p axis

Fig. 6

Bupivacaine-induced influences in gastric cancer cells are largely reversed by the introduction of circ_0000376 overexpression plasmid or anti-miR-145-5p. a and b The transfection efficiencies of circ_0000376 and anti-miR-145-5p in gastric cancer cells were assessed by qRT-PCR. c-j We treated AGS and HGC27 cells with Bupivacaine (10 μg/mL, 48 h), Bupivacaine + vector, Bupivacaine + circ_0000376, Bupivacaine + anti-NC or Bupivacaine + anti-miR-145-5p. c Cell viability in different groups was detected by CCK8 assay. d Caspase-3 activity was measured using Caspase-3 activity detection kit. e The apoptosis rate was analyzed by flow cytometry. f and g Transwell migration and invasion assays were implemented to analyze the migration and invasion abilities of gastric cancer cells. h and i The ECAR was analyzed by the Seahorse XF 96 Extracellular Flux Analyzer to assess the glycolytic metabolism of gastric cancer cells. j The expression of GLUT1 and LDHA in AGS and HGC27 cells was detected by Western blot assay. *P < 0.05, **P < 0.01, ***P < 0.001

Back to article page